SCHEMBL703198

SCHEMBL703198

CCOC(=O)c1cc2c(OC)cc(OC)cc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.58
ALDH1A1 P00352 7/20 0.58
RAB9A P51151 6/20 0.58
HPGD P15428 5/20 0.58
NPC1 O15118 5/20 0.58
LMNA P02545 3/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
HTT P42858 1/20 0.58
IDO1 P14902 1/20 0.53
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28844724 0.86 ALDH1A1 (0.58) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL6223883 0.85 ULK1 (0.66) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL30995200 0.85 ALDH1A1 (0.56) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL6704950 0.82 KDM4E (0.54) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL8200409 0.82 ALDH1A1 (0.53) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL8198301 0.82 KDM4E (0.47) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL1144683 0.81 IDO1 (0.55) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL699482 0.81 FLT3 (0.60) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL28595395 0.80 ULK1 (0.74) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL29540084 0.80 IDO1 (0.54) KDM4EALDH1A1RAB9AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2367817-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-09-28 EP disclosed
WO-2010065310-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-06-10 WO disclosed
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MADRIGAL PHARMACEUTICALS, INC. 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT KDM4E 2709/4885ALDH1A1 586/4885RAB9A 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.